George Clinical, a leading full-service CRO in the US and Asia-Pacific region, is pleased to announce that Matthew Reabold, Sr. has been promoted to the Head of Business Development, USA.

乔治临床( George Clinical ), headquartered in Sydney, Australia, operates in fifteen countries around the world and has major operational hubs in the USA, East Asia, China, and India. Matthew, who is USA based, will be leading our Business Development team in North America and Europe. Matthew came to 乔治临床( George Clinical ) with 20 years on the sponsor side of the business and understands the challenges facing biopharma companies when executing and outsourcing their clinical trials. The last ten years have been spent developing solutions in partnership with pharma and biotech clients, working for some large and smaller CRO’s. He brings a broad spectrum of knowledge to the team including expertise in oncology, renal, diabetes, cardiovascular and CNS. Matthew states, “This is truly a great opportunity to work with and lead an organization with a strong people first culture that focuses on improving the medical care of patients while contributing to scientific advancement in chronic diseases and oncology. Our model is unique within the CRO industry in that we lead with science and a singular focus on translating that science into operational value for our clients.”

“We are excited that Matthew, with his focus on customer service and his abilities to assemble a strong team, will lead Business Development in the USA to accomplish our goals as a global organization,” said Mr. Sean Hart, Managing Director, USA and Global Head of Late Phase Studies.

About 乔治临床( George Clinical )

乔治临床( George Clinical ) is a leading independent Asia-Pacific based clinical research organization (CRO) with global capabilities differentiated by scientific leadership and extensive site networks. With operations in 13 countries and staff operating in 15 countires, 乔治临床( George Clinical ) provides the full range of clinical trial services to pharmaceutical, medical device, and biotech customers, for all trial phases, registration, and post-marketing trials. 乔治临床( George Clinical ) combines scientific and clinical leadership with expert trial delivery capability to create a distinctive world-class service. In recent years, 乔治临床( George Clinical ) has managed more than 40,000 patients in trials across more than 1,700 sites. George Clinical’s parent organization, The George Institute for Global Health, is a leader in chronic disease research, with a global network of experts with whom 乔治临床( George Clinical ) engages. 乔治临床( George Clinical ) delivers an operationally supported, internationally recognized scientific leadership service, bringing together an extensive series of investigator networks that allow 乔治临床( George Clinical ) to provide customizable clinical trial excellence from trial design through all aspects of delivery.

Contact: mreabold@georgeclinical.com
Website: georgeclinical.cn
LinkedIn:  https://www.linkedin.com/company/george-clinical-pty-ltd
Twitter: https://twitter.com/george_clinical
Facebook: https://www.facebook.com/georgeclinical

For more information, contact:
Donna McDonnell
Business Development Administrator
T 901 259 0888 | M 901 229 5345
E dmcdonnell@georgeclinical.com
W georgeclinical.cn | www.georgeinstitute.org